KM
BNGO icon

Kalos Management’s Bionano Genomics BNGO Stock Holding History

Kalos Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43
Closed -$35K – 57
2022
Q2 		$35K Sell
43
-1
-2% -$1.03K 0.05% 129
2022
Q1 		$68K Buy
44
+12
+38% +$16.2K 0.05% 159
2021
Q4 		$105K Buy
32
+1
+3% +$2.67K 0.03% 280
2021
Q3 		$101K Buy
31
+4
+15% +$14K 0.03% 279
2021
Q2 		$112K Buy
27
+8
+42% +$31.6K 0.05% 252
2021
Q1 		$74K Buy
+19
New +$107K 0.02% 287

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Kalos Management's BNGO Position: Q3 2022 in Review

Kalos Management sold out of Bionano Genomics (BNGO) in Q3 2022, closing a stake of 43 shares — an estimated $35K sold.

Kalos Management first reported a position in BNGO in Q1 2021 and held it in 6 quarters. The position peaked at $112K in Q2 2021. 140 funds tracked by Wall St. Rank hold BNGO as of Q3 2022.

  • Kalos Management reported no remaining Bionano Genomics position as of Q3 2022 after selling out during the quarter.
  • Kalos Management sold 43 Bionano Genomics shares in Q3 2022, an estimated $35K.
  • Kalos Management first reported a position in Bionano Genomics in Q1 2021 and held it in 6 quarters.
  • Kalos Management's Bionano Genomics position peaked at $112K in Q2 2021.
  • 140 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2022.

Based on Kalos Management's 13F filing for Q3 2022, filed 21 Nov 2022.